Females and people with decrease physique weight have higher outcomes.
New analysis offered at this yr’s European Congress on Obesity (held on-line, Could 10-13) exhibits that therapy with the drug semaglutide reduces physique weight in adults with chubby or weight problems, regardless of their baseline traits.
Nonetheless, the examine confirmed that feminine individuals had barely higher outcomes than males and in addition that individuals with the bottom beginning physique weight responded barely higher than these with greater physique weights. The examine is by Professor Robert Kushner, Feinberg College of Medication, Northwestern College, Chicago, IL, USA, and colleagues.
Semaglutide is already permitted for therapy for kind 2 diabetes in a number of nations, and is beneath improvement for therapy of weight problems. The STEP trials revealed over the previous yr have established the efficacy and security of semaglutide 2.4 mg in treating folks with chubby and weight problems. On this new evaluation of information from the STEP 1 trial (see hyperlink beneath), the researchers investigated weight reduction in subgroups of individuals based mostly on their baseline traits.
In STEP 1, adults with out kind 2 diabetes with both a physique mass index (BMI) of at the very least 27 kg/m² plus a number of weight-related comorbidities, or a BMI of 30 kg/m² or above, had been enrolled. Contributors had been randomized to a once-weekly injection of semaglutide 2.4 mg or placebo, each plus life-style intervention, for 68 weeks.
The authors checked out what proportions of the individuals achieved completely different ranges of weight reduction with semaglutide from baseline to week 68 (?20%, 15-<20%, 10-<15%, or 5-<10%) when grouped by completely different baseline traits (age, intercourse, race [White, Asian, Black or African American, or other], physique weight, BMI, waist circumference and glycaemic standing [normal blood sugar, or pre-diabetes]). Imply % weight reduction with semaglutide from baseline to week 68 was analyzed individually by intercourse (male, feminine) and baseline physique weight (?115 kg, 100-<115 kg, 90-<100 kg, <90 kg) subgroup.
The unique examine included 1,961 randomized individuals (imply age 46 years, physique weight 105.3 kg, BMI 37.9 kg/m²; 74.1% feminine). For categorical weight reduction, the noticed proportions of individuals with ?20%, 15-<20%, 10-<15% and 5-<10% weight reduction at week 68 had been 34.8%, 19.9%, 20.0% and 17.6% with semaglutide vs 2.0%, 3.0%, 6.8% and 21.2% with placebo, respectively.
The distribution of individuals throughout weight-loss teams didn’t look like affected by any baseline traits, besides intercourse and baseline physique weight. Imply % weight reduction at week 68 with semaglutide was better amongst females (-18.4%) than males (-12.9%), and in individuals with decrease vs greater baseline physique weight (-18.6% for individuals with <90 kg physique weight at baseline; -13.9% for individuals with ?115 kg baseline physique weight).
The authors conclude: “We discovered that weight reduction with once-weekly injections of semaglutide 2.4 mg was seen in all subgroups evaluated and was usually not influenced by baseline traits. The exceptions had been intercourse and baseline physique weight; feminine intercourse and a low baseline physique weight had been related to a barely better response to semaglutide. These information assist the use of semaglutide 2.4 mg throughout a broad inhabitants of sufferers with chubby or weight problems.”